a Rheumatology Division , Hospital Universitario Central de Asturias (HUCA) , Oviedo , Spain.
b Dermatology Division , Hospital Alvarez Buylla , Mieres , Asturias , Spain.
Expert Opin Biol Ther. 2018 Sep;18(9):931-935. doi: 10.1080/14712598.2018.1504919. Epub 2018 Jul 31.
Ustekinumab (UST) is a recently approved drug for the treatment of psoriatic arthritis (PsA). The ACR response rates in randomized clinical trials (RCTs) with this drug have been slightly lower than that reported in RCTs of anti-TNF and anti-IL17 therapies. Therefore, the position that this drug may occupy in the treatment algorithms of PsA is not clear. More information is needed on the true efficacy of this agent under real clinical practice conditions. In this review of real-world evidence studies, it is shown that UST is effective and safe to treat PsA; nevertheless, it is necessary to homogenize the way in which the main outcomes and treatment objectives of these studies are presented.
乌司奴单抗（UST）是一种最近被批准用于治疗银屑病关节炎（PsA）的药物。与抗 TNF 和抗 IL17 治疗的 RCT 相比，该药物的 RCT 中的 ACR 反应率略低。因此，该药在 PsA 治疗方案中的地位尚不清楚。需要更多关于该药物在真实临床实践条件下真实疗效的信息。在对真实世界证据研究的回顾中，表明 UST 治疗 PsA 是有效且安全的；然而，有必要统一这些研究呈现主要结局和治疗目标的方式。
